Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 17/20 | 0.86 |
| ▸ | MMP8 | P22894 | 7/20 | 0.86 |
| ▸ | MMP13 | P45452 | 1/20 | 0.86 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.86 |
| ▸ | MMP2 | P08253 | 17/20 | 0.68 |
| ▸ | MMP12 | P39900 | 6/20 | 0.63 |
| ▸ | MMP14 | P50281 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716323 | 1.00 | MMP9 (0.86) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL698930 | 1.00 | MMP9 (0.86) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL14602275 | 0.92 | MMP9 (1.00) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL14602271 | 0.92 | MMP9 (1.00) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL31609930 | 0.92 | MMP9 (1.00) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| Carglumic Acid SCHEMBL7824179 | 0.90 | MMP9 (0.71) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL7906607 | 0.89 | MMP9 (0.78) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| Toluene SCHEMBL7906483 | 0.89 | MMP9 (0.78) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL6574668 | 0.88 | MMP9 (0.86) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL697840 | 0.86 | MMP9 (0.74) | MMP9MMP8MMP13ADAMTS4MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106432188-A | Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide | 青岛辰达生物科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| EP-1436371-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-07-14 | — | — | EP | claimed |
| WO-2002099023-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2002-12-12 | — | — | WO | claimed |
| JP-6107604-A | — | — | None | — | — | JP | disclosed |
| CN-106432188-A | Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide | 青岛辰达生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| CN-102274130-A | Application of n- benzene sulfonyl-l-glutamic acid or saline thereof | — | 2011-12-14 | — | — | CN | disclosed |
| CN-102266269-A | Parakeratosis inhibitor and external composition for skin | — | 2011-12-07 | — | — | CN | disclosed |
| CN-1886114-B | Parakeratosis inhibitor and composition for external use on skin | SHISEIDO CO LTD | 2011-08-10 | — | — | CN | disclosed |
| EP-0906906-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-PIPERAZINECARBOXYLIC ACID DERIVATIVES | TORAY INDUSTRIES (JP) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002099023-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2002-12-12 | — | — | WO | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5952503-A | Method for producing optically-active 2-piperazinecarboxylic acid derivatives | TORAY INDUSTRIES, INC. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0906906-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-PIPERAZINECARBOXYLIC ACID DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1999-04-07 | — | — | EP | disclosed |
| JP-H06107604-A | PRODUCTION OF OPTICALLY ACTIVE 1-@(3754/24)4-HALOGENOPHENYL) ETHYLAMINE | TORAY IND INC | 1994-04-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | MMP9 1373/4885MMP8 2925/4885MMP13 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.